Juno Therapeutics (NASDAQ:JUNO) has tumbled 1.35% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 4.02% in the last four weeks. The stocks have underperformed the S&P 500 by 0.17% during the past week but Juno Therapeutics (NASDAQ:JUNO) it has outperformed the index in 4 weeks by 3.07%.
Juno Therapeutics (NASDAQ:JUNO): The stock opened at $43.20 on Friday but the bulls could not build on the opening and the stock topped out at $43.64 for the day. The stock traded down to $41.91 during the day, due to lack of any buying support eventually closed down at $42.40 with a loss of -1.26% for the day. The stock had closed at $42.94 on the previous day. The total traded volume was 1,709,394 shares.
The company shares have dropped -18.02% from its 1 Year high price. On Jun 30, 2015, the shares registered one year high at $59.60 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $41.25 and the 200 Day Moving Average price is recorded at $39.52.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Bishop Hans Edgar, director officer (CEO & President) of Juno Therapeutics, Inc., had unloaded 90,750 shares at an average price of $47.38 in a transaction dated on June 9, 2016. The total value of the transaction was worth $4,299,735.
Many analysts have stated their opinion on the company shares. Raymond James initiates coverage on Juno Therapeutics (NASDAQ:JUNO). The rating major has initiated the coverage with outperform rating on the shares. The rating by the firm was issued on June 2, 2016. Currently the company Insiders own 15.26% of Juno Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.34% . Institutional Investors own 58.19% of Juno Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -2.94%.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.